FDA grants orphan-drug status to ZIOPHARM cancer drug

05/11/2008 | Forbes

The FDA has granted ZIOPHARM Oncology orphan-drug status for Palifosfamide, a treatment for soft-tissue sarcoma. The injectable form of the drug is currently in Phase II trials, while Phase I studies for an oral formulation are expected to begin in early 2009.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT